Treatment and Care

The Federal Bureau of Prisons (BOP) Stepwise Approach for Detecting, Evaluating, and Treating Chronic Hepatitis B Virus Infection provides recommendations for the medical management of federal inmates with chronic hepatitis B, or who are otherwise at risk of infection. The treatment of chronic hepatitis B in pregnancy or with hepatocellular carcinoma is beyond the scope of this guideline. For a more in-depth discussion of vaccination strategies and management of blood and body fluid exposures, the reader should refer to the BOP Clinical Practice Guidelines for those topics.

This report summarizes trends in cephalosporin susceptibility among N. gonorrhoeae isolates in the United States during 2000--2010 using data from the Gonococcal Isolate Surveillance Project (GISP). During that period, the percentage of isolates with elevated minimum inhibitory concentrations (MICs) to cephalosporins (=0.25 µg/mL for cefixime and =0.125 µg/mL for ceftriaxone) increased from 0.2% in 2000 to 1.4% in 2010 for cefixime and from 0.1% in 2000 to 0.3% in 2010 for ceftriaxone.

4 waiting room posters to encourage patients to speak with their doctor about latent TB. The posters are available in English and Chinese.

This Toolkit is the principal outcome of the second phase of the EPT law project. It is intended as a resource for voluntary use by government officials at the state and local levels, their public and private sector partners, and others who are interested in adopting or facilitating the implementation of statutes or regulations that permit EPT in clinical practice. This Toolkit is not designed to provide specific legal guidance or advice and does not represent the official legal positions of federal, state, or local governments.

This serial reports on the Medical Monitoring Project (MMP). The MMP was designed to be a nationally representative, population-based surveillance system to assess clinical outcomes and behavioral outcomes among persons with HIV infection who are receiving medical care in the United States. This report covers data collected during June 2007 to September 2008 for patients who received medical care in 2007. Findings indicate that in 2007, most persons with HIV infection who were receiving medical care were taking antiretroviral therapy (ART), and had some form of health insurance or coverage.

This slide set discusses use of the Ryan White Care Act (RWCA) to provide treatment of hepatitis C coinfection in persons living with HIV. It presents an overview of viral hepatitis, the basics of hepatitis C compared with hepatitis A and B, acute and chronic infection, prevention, HCV treatment and side effects of treatment, treatment decisions,, barriers to treatment, and increasing access to treatment through the RWCA.

This report outlines some of the strategies, tools and policies that have supported the scaling up of treatment during the past decade as well as those that can address persistent or new challenges. The results are presented from a 23-country survey of how consistently these strategies are being implemented. The findings demonstrate encouraging progress by some health ministries in adopting many of the enabling policies needed to facilitate scale-up and improve care. Nevertheless, the adoption and implementation of these strategies, tools and policies are lagging in some countries.

This report presents guidelines for diagnosing, evaluating, and treating hepatitis C in persons incarcerated in Federal government prisons. It explains the transmission of hepatitis C virus (HCV), acute HCV infection and its treatment; chronic HCV infection; and a stepwise approach for detecting, evaluating, and treating chronic HCV infection. It discusses the direct-acting antiviral agents for treatment of chronic HCV infection that were FDA approved in May 2011, and their use, the indications and contraindications for triple therapy, managing side effects, and monitoring treatment response.

This poster states three important facts people should know about hepatitis C: it's a leading cause of liver cancer, millions of Americans have it, but don't know it, and treatments can eliminate the virus. The poster advises individuals to talk to their doctor about getting tested. The poster is also available in a smaller size, 26" x 36", at http://www.cdc.gov/knowmorehepatitis/media/pdfs/poster-facts24x36.pdf.